Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod

被引：16

作者：

Evangelopoulos, Maria Eleftheria ^{[1
,2
,3
]}

Miclea, Andrei ^{[2
,3
]}

Schrewe, Lisa ^{[2
,3
]}

Briner, Myriam ^{[2
,3
]}

Salmen, Anke ^{[2
,3
]}

Engelhardt, Britta ^{[4
]}

Huwiler, Andrea ^{[5
]}

Chan, Andrew ^{[2
,3
]}

Hoepner, Robert ^{[2
,3
]}

机构：

[1] Univ Athens, Eginit Univ Hosp, Dept Neurol, Athens, Greece

[2] Bern Univ Hosp, Dept Neurol, Bern, Switzerland

[3] Univ Bern, Bern, Switzerland

[4] Univ Bern, Theodor Kocher Inst, Bern, Switzerland

[5] Univ Bern, Inst Pharmacol, Bern, Switzerland

来源：

CNS NEUROSCIENCE & THERAPEUTICS | 2018年 / 24卷 / 10期

基金：

瑞士国家科学基金会;

关键词：

Disease activity; Disease reactivation; FTY; Gilenya; MS relapse; MS;

D O I：

10.1111/cns.12992

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

引用

页码：984 / 986

页数：3

共 7 条

[1] Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingorimod MS rebound [J].

Cavone, Leonardo ;

Felici, Roberta ;

Lapucci, Andrea ;

Buonvicino, Daniela ;

Pratesi, Sara ;

Muzzi, Mirko ;

Hakiki, Bahia ;

Maggi, Laura ;

Peruzzi, Benedetta ;

Caporale, Roberto ;

Annunziato, Francesco ;

Amato, Maria Pia ;

Chiarugi, Alberto .

BRAIN BEHAVIOR AND IMMUNITY, 2015, 50 :78-86

[2] Clinical Pharmacokinetics of Fingolimod [J].

David, Olivier J. ;

Kovarik, John M. ;

Schmouder, Robert L. .

CLINICAL PHARMACOKINETICS, 2012, 51 (01) :15-28

[3] Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis [J].

Gunduz, Tuncay ;

Kurtuncu, Murat ;

Eraksoy, Mefkure .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 11 :1-3

[4] Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment [J].

Hatcher, Stacy Ellen ;

Waubant, Emmanuelle ;

Nourbakhsh, Bardia ;

Crabtree-Hartman, Elizabeth ;

Graves, Jennifer S. .

JAMA NEUROLOGY, 2016, 73 (07) :790-794

[5] The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives [J].

Huwiler, Andrea ;

Zangemeister-Wittke, Uwe .

PHARMACOLOGY & THERAPEUTICS, 2018, 185 :34-49

[6] Risk of relapse phenotype recurrence in multiple sclerosis [J].

Kalincik, Tomas ;

Buzzard, Katherine ;

Jokubaitis, Vilija ;

Trojano, Maria ;

Duquette, Pierre ;

Izquierdo, Guillermo ;

Girard, Marc ;

Lugaresi, Alessandra ;

Grammond, Pierre ;

Grand'Maison, Francois ;

Oreja-Guevara, Celia ;

Boz, Cavit ;

Hupperts, Raymond ;

Petersen, Thor ;

Giuliani, Giorgio ;

Iuliano, Gerardo ;

Lechner-Scott, Jeannette ;

Barnett, Michael ;

Bergamaschi, Roberto ;

Van Pesch, Vincent ;

Amato, Maria Pia ;

Van Munster, Erik ;

Fernandez-Bolanos, Ricardo ;

Verheul, Freek ;

Fiol, Marcela ;

Cristiano, Edgardo ;

Slee, Mark ;

Rio, Maria Edite ;

Spitaleri, Daniele ;

Alroughani, Raed ;

Gray, Orla ;

Saladino, Maria Laura ;

Flechter, Sholmo ;

Herbert, Joseph ;

Cabrera-Gomez, Jose Antonio ;

Vella, Norbert ;

Paine, Mark ;

Shaw, Cameron ;

Moore, Fraser ;

Vucic, Steve ;

Savino, Aldo ;

Singhal, Bhim ;

Petkovska-Boskova, Tatjana ;

Parratt, John ;

Sirbu, Carmen-Adella ;

Rozsa, Csilla ;

Liew, Danny ;

Butzkueven, Helmut .

MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (11) :1511-1522

[7] A safety and pharmacokinetic study of intravenous natalizumab in patients with MS [J].

Sheremata, WA ;

Vollmer, TL ;

Stone, LA ;

Willmer-Hulme, AJ ;

Koller, M .

NEUROLOGY, 1999, 52 (05) :1072-1074

← 1 →